ArticleAnimal models and experimental medicine2026
An in vivo assay for osteoclast activity using mouse calvaria.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An in vivo assay for osteoclast activity using mouse calvaria.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Osteoclasts are essential for maintaining healthy bone. Pathological elevation of osteoclastogenesis or osteoclast activity can cause osteoporosis and increase the risk of bone fracture. However, a few options are available for directly measuring osteoclast activity in vivo to test interventions that may affect osteoclasts. Here, we describe an in vivo method to measure osteoclast-mediated bone loss targeted at normal mouse calvaria. The method employs a novel procedure for measuring osteoclast resorption pits using micro-computed tomography. The potential utility of this mouse calvaria model to assess therapies targeting osteoclasts was validated using zoledronic acid, which is a nitrogen-containing bisphosphonate drug used to treat osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.